Ocugen GA Trial Advances Toward Phase 3 - Takeaway - MDSpire
Clinical Guidelines

Ocugen GA Trial Advances Toward Phase 3

Ocugen reports positive Phase 2 data for its OCU410 gene therapy in geographic atrophy

  • May 1, 2026

  • 3 min

Share

  • 1

    OCU410 is a novel gene therapy for geographic atrophy (GA).

  • 2

    Phase 2 trial showed a 31% reduction in GA lesion growth.

  • 3

    Treatment requires only one subretinal injection.

  • 4

    No serious adverse events were reported.

  • 5

    55% of patients had a significant reduction in lesion size.

  • 6

    Phase 3 trial is set to begin in late

  • 7

    GA prevalence is projected to increase with aging populations.

Original Source(s)

Ocugen GA Trial Advances Toward Phase 3

  • May 1, 2026

Related Content

GA Gene Therapy Interest Increases

Phase I trial results of PulseSight Therapeutics’ PST-611 to be presented at ARVO 2026

  • May 1, 2026

  • 2 min
TULIP: A New Approach to IOP Reduction

Low-power ultrasound biomodulation may offer a noninvasive, repeatable strategy to lower IOP without tissue destruction.

Emerging Technologies in Continuous IOP Monitoring

Wearable and implantable devices offer new data on pressure variability, though barriers to routine use persist.